Insider Transactions in Q4 2023 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2023
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Direct |
30,000
-5.0%
|
$1,410,000
$47.87 P/Share
|
|
Dec 20
2023
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+3.9%
|
-
|
|
Oct 23
2023
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
39,878
-13.91%
|
$1,276,096
$32.78 P/Share
|
|
Oct 23
2023
|
Thomas Richard Kassberg CBO & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
39,878
+12.21%
|
$239,268
$6.86 P/Share
|
|
Oct 19
2023
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Direct |
47,853
-7.39%
|
$1,579,149
$33.52 P/Share
|
|
Oct 19
2023
|
Emil D Kakkis President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,853
+6.89%
|
$287,118
$6.86 P/Share
|
|
Oct 09
2023
|
Howard Horn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,366
+50.01%
|
-
|